Objectives: GB virus-C/hepatitis G virus (GBV-C/HGV), collectively known as GBV-C, has been reported to be associated with non-A-E hepatitis. The aim of this study was to determine the rate of infection and genotypic characteristics of GBV-C among Kuwaiti and Jordanian blood donors. Methods: A total of 334 plasma/serum samples from healthy blood donors in Kuwait (n = 130) and Jordan (n = 204) were screened using RT-PCR/nested PCR of the 5′-untranslated region (5′-UTR). Phylogenetic analysis was conducted by sequencing the 5′-UTR region of the randomly picked clones representative of the two populations. Results: The results obtained showed that the rate of GBV-C infection in healthy Kuwaiti and Jordanian blood donors was 24.6 and 9.8%, respectively. Sequence analysis of the 5′-UTR using 4 and 6 clones from healthy Kuwaiti and Jordanian blood donors, respectively, revealed the prevalence of the European/North American genotype 2 when compared to the 6 reference genotypes in GenBank. Conclusion: GBV-C/HGV was detectable at rates relatively comparable with other regions in the world in Kuwaiti and Jordanian blood donors, although the significance of which remains controversial. More interesting is the dominance of GBV-C genotype 2 among the two populations, which remains to be explained.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.